Navigation Links
Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
Date:4/8/2013

RIDGEFIELD, Conn., April 8, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced that data from its pivotal STARTVerso™ 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress™ 2013: 48th Annual Meeting of the European Association for the Study of the Liver (EASL), taking place from April 24-28 in Amsterdam, The Netherlands.

The STARTVerso™ 1 trial evaluated faldaprevir (BI 201335), an investigational oral protease inhibitor specifically designed to target and inhibit viral replication in the liver, in combination with pegylated interferon and ribavirin (PegIFN/RBV). The study was conducted in treatment-naïve patients with genotype-1 infection, the most common and one of the most challenging types of hepatitis C to cure.

Further sub-analyses from Boehringer Ingelheim's interferon-free Phase 2b SOUND-C2 study will also be presented at the Congress. The SOUND-C2 trial evaluated the interferon-free combination of faldaprevir and BI 207127, an investigational non-nucleoside NS5B polymerase inhibitor, plus ribavirin.

Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. Through robust science, Boehringer Ingelheim's goal is to find answers to the ongoing challenges faced by a diverse population of patients with hepatitis C.

The STARTVerso™ 1 abstract can be accessed through the Congress website beginning on April 23 and the SOUND-C2 abstracts can be accessed today. Oral PresentationStudyLead AuthorPresentation DetailsSTARTVerso™ 1

P. Ferenci

Embargoed until April 23 at 12:00PM CET (6:00AM ET)Poster Presentations'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
2. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
3. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
4. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
5. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
6. Pharmaceutical Leader Boehringer Ingelheim Selects Republica as Cross-Cultural Marketing Agency
7. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
8. FDA Advisory Committee Recommends Approval for Boehringer Ingelheims Olodaterol for Maintenance Treatment of COPD
9. Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems
10. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
11. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
(Date:12/22/2014)... LAWRENCE, Mass. , Dec. 22, 2014 /PRNewswire/ ... a leading manufacturer of innovative dialysis products, announced ... (FDA) has cleared its System One™ to perform ... sleeping, known as home nocturnal hemodialysis. NxStage,s® System ... cleared by the FDA for this indication. ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... than 11,000 churches since,its launch in April, ... In preparation for flu,season, The COSHAR Foundation ... vaccine-preventable illnesses -- including the flu. The,Foundation,s ... awareness,campaign, Protecting our Future: The COSHAR Foundation ...
... 10 Raptor,Pharmaceuticals Corp. ("Raptor" or the ... the Company has entered into an agreement ... of France to,evaluate Raptor,s proprietary delayed-release cysteamine ... trial in patients with Huntington,s,Disease ("Huntington,s"). CHU ...
Cached Medicine Technology:The COSHAR Foundation Urges Parents to Ensure Children Are Up-to-Date on Vaccinations 2Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 2Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 3Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 4Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 5Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 6
(Date:12/26/2014)... Plugin and template developers from Pixel Film ... Final Cut Pro X. , “TransPack Volume 5 gives users ... off an industry professional look” Said Christina Austin, CEO of ... Volume 5, a new level of professionalism will become the ... 50 Final Cut Pro X transitions featuring organic animations. Choose ...
(Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
(Date:12/25/2014)... The click strand woven ... and durability. Today, the business announces a click ... until Jan. 30, 2015. , Click strand woven ... BambooFlooringChina.com is a well-known brand in the bamboo ... find a reliable bamboo flooring supplier. , “We ...
(Date:12/25/2014)... 2014 “Every three months the trends for ... sweetheart evening dress will be one of the hottest styles ... Yunx.co.uk says. Today, the company releases 26 A-line sweetheart evening ... 80% off. , “We are trying our best to ... our latest designs. Along with affordable prices, we provide discounted ...
(Date:12/25/2014)... Recently, BellasDress has launched ... wedding dresses. BellasDress has chosen their best-selling lace wedding ... for the holiday season. , Now, BellasDress.com features ... gowns here at discount prices. The business hopes everyone ... website. , “All our elegant products are ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... SINGAPORE, Oct. 31 Flextronics International,Ltd. (Nasdaq: ... Flextronics,s,previously announced acquisition of Solectron Corporation on October ... 0.50% Convertible,Senior Notes due 2034 (CUSIP Nos. 834182 ... Convertible Senior Notes Series B due 2034 (CUSIP ...
... Impact,Medical Solutions, Inc. (OTC Bulletin Board: IMSU), ... Craig W. Lunsman to its board,of directors. Mr. ... William,Jamieson Group, LLC, a consulting group that provides ... private small cap companies.,As an outside director, Mr. ...
... PETA Talking Points, Discourages Donations to,Legitimate Cancer Charities, ... today,s report on global causes of cancer from ... for Consumer Freedom is urging,them to be skeptical ... calling itself "The Cancer Project." A project of ...
... data finds no link to most common illnesses , ... do not increase the risk of cancers, connective tissue ... researchers. , A team from the International Epidemiology Institute ... in Nashville, Tenn., reviewed available research on the safety ...
... UCLA and Vanderbilt football coach Red Sanders, I just want ... 15-year-old athlete, New research indicates that young athletes find playing ... maximum effort is far more important and has a bigger ... terms of athletes ratings of how much fun they had ...
... Oct. 31 Every day that goes,by without progress ... wasted, and more damage is done to an already,weakened ... pro tem introduced their health reform plans at the ... a vigorous debate that,finally would result in health coverage ...
Cached Medicine News:Health News:Flextronics Announces Change in Control Repurchase Offer for Solectron's 0.50% Senior Convertible Notes 2Health News:Impact Medical Solutions Announces Appointment of New Director 2Health News:Impact Medical Solutions Announces Appointment of New Director 3Health News:Consumer Alert: 'Cancer Project' Organization Is a Deceptive Animal Rights Group 2Health News:Little Evidence Silicone Breast Implants Harm Health 2Health News:Motivational coaching climate outscores winning for young athletes 2Health News:Statement by Bruce Bodaken, Chairman & CEO, Blue Shield of California 2
...
...
EDM Ventricular Drainage Kit, with Drip Chamber with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in ...
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
Medicine Products: